

The presence of oligoclonal IgG bands in human CSF during the course of neurological diseases

M. Haertle · U. Kallweit · M. Weller ·
M. Linnebank

Received: 16 November 2013 / Revised: 20 December 2013 / Accepted: 21 December 2013 / Published online: 22 January 2014
© Springer-Verlag Berlin Heidelberg 2014

Abstract The analysis of cerebrospinal fluid (CSF) is an important tool for the diagnosis of neurological diseases. However, there is limited knowledge about the representativity of a single oligoclonal band (OCB) analysis for a neurological disease during its clinical course. In this study, we analyzed the presence of OCB in the CSF of patients who underwent lumbar puncture more than once. We retrospectively analyzed anonymized data from serial 17,002 CSF analyses done in the CSF laboratory of the Department of Neurology, University Hospital Zurich. We included cases with documented diagnosis in whom OCB were determined more than once. We included 144 patients. The median time span between the first and second OCB analysis was 274 days (range, 1–3,533 days). The result of the second OCB analysis was identical in 109 cases, and different in 35 (24 %). Twenty-five patients acquired and ten patients lost OCB over time. Three of 24 MS patients did not show OCB at the first CSF analysis, but in the second. In the entire group, newly occurring OCB were often associated with new symptoms or occurred after the acute phase of CNS infectious diseases, supposedly as a consequence of the immune reaction. A loss of OCB was often associated with remissions from diseases, e.g., during effective treatment. In patients with neurological diseases, both initially positive and negative OCB results may change over time, which often parallels the clinical condition. Such variability must be taken into account for the interpretation of OCB results.

Keywords Oligoclonal band · Multiple sclerosis · Cerebrospinal fluid

Introduction

The primary function of cerebrospinal fluid (CSF) is protecting the central nervous system (CNS) from mechanical injury. Moreover, it is important for homeostatic regulation, helps in maintaining intracerebral pressure at a constant level, circulates nutrients, and rinses waste products from the brain parenchyma. In humans, the majority of CSF originates from the four choroid plexus in the ventricles, from parenchyma of the brain and of the spinal cord, and from ependymal lining of the ventricles [1, 2]. CSF is constantly produced and mainly drained through cisternae, subarachnoid space, and arachnoid villi into the venous blood. The transfer of proteins, such as albumin, antibodies, or complement, from blood into CSF follows passive diffusion as a function of molecular size. Restriction of this transfer from blood into the CSF is called the blood–CSF fluid barrier [3, 4]. While leukocytes can cross vessel walls to reach the perivascular space (PVS) as part of normal immune surveillance, their progression across the glia limitans into the brain parenchyma depends on perivascular antigen recognition, inducing ectoenzymes such as metalloproteinases [5–7]. In neurological disorders, CSF analysis is an important tool for diagnosis [4]. Typical CSF signs of an acute CNS disease include increased CSF cell count and increased albumin CSF/serum concentration quotient, the latter indicating an impairment of the blood–CSF barrier, as albumin is exclusively produced in the liver and thus can only occur in the CNS by passing the barrier. Immune reactions in the CNS include an intrathecal antibody synthesis of immunoglobulins originating from

M. Haertle (✉) · U. Kallweit · M. Weller · M. Linnebank
Department of Neurology, University Hospital Zurich,
Frauenklinikstrasse 26, 8091 Zurich, Switzerland
e-mail: m.haertle@gmx.de

M. Linnebank
e-mail: michael.linnebank@usz.ch

perivascular infiltrates of B-lymphocytes. Beneath the synthesis of specific antibodies in infectious diseases, the humoral immune response in the CNS may lead to poly-specific/unspecific IgG/IgA/IgM patterns. Oligoclonal IgG detected as oligoclonal bands (OCB) upon isoelectric CSF focusing with or without corresponding OCB in the serum reflect an intrathecal humoral immune response with or without a corresponding systemic immune reaction and is often seen in autoimmune CNS inflammation including multiple sclerosis (MS), Sjögren’s syndrome, systemic lupus erythematosus (SLE), or neurosarcoidosis, but also in CNS infections [8–10]. Due to an improvement of MRI techniques, decreasing emphasis is placed on the value of CSF OCB in the diagnosis and study of MS [11]. Nevertheless, beneath the value of standard CSF analysis for the exclusion of differential diagnoses, OCB analysis may provide relevant information in the diagnostic process of autoimmune diseases. Positive OCB provide direct evidence of immune reactions in the CNS while imaging provides only indirect information. OCB are present in approximately 90–95 % of MS patients, and thereby a positive result supports the diagnosis of MS against, for example, vascular lesions [12, 13]. Also, within the group of autoimmune inflammatory diseases, the analysis of OCB may be helpful for differential diagnoses. For example, neuromyelitis optica (NMO) may resemble MS. OCB might be positive in NMO, but much less often than in MS, and therefore the determination of OCB could be helpful in distinguishing MS from NMO [14, 15].

CSF analysis is usually performed for diagnostic purposes and by lumbar puncture (LP). As it is painful and invasive, it is only performed when clearly indicated. Therefore,

longitudinal data on changes of OCB synthesis during the clinical course of an autoimmune disease are limited [16–18]. The aim of this study was to examine to what extent OCB results change intraindividually over time and with which clinical conditions such changes might be associated.

Methods


Patients

We retrospectively analyzed 17,002 anonymized serial lumbar punctures documented in the CSF database, Department of Neurology, University Hospital Zurich, after pseudonymization. This database includes demographic (age, gender), clinical (confirmed or suspected diagnosis), and CSF data from 1992 on. Cases were included when ≥ 2 paired CSF and serum samples were analyzed for OCB and the diagnosis was documented in the database.

OCB definitions

OCB were assessed by isoelectric focusing electrophoresis with anti-human-IgG and silver stain (PhastSystem, GE Healthcare, Heidelberg, Germany). OCB were identified by two experienced raters in consensus reading and, in rare case of differences, by the laboratory supervisor. *OCB negative (OCB neg)* was defined as no OCB detection in CSF and serum (Fig. 1a). *OCB positive (OCB pos)* was defined as ≥ 1 OCB in the CSF, but no OCB in corresponding serum (Fig. 1a). *OCB pos/pos* was defined as ≥ 1

Fig. 1 Paired CSF and serum samples of OCB. **a** Two sets of paired CSF (C) and serum samples (S) showing the patterns of *OCB pos*, *OCB neg*. **b** Two sets of paired CSF and serum sample illustrating the pattern of *OCB pos/pos* and *OCB pos+/pos*. Isoelectric focusing electrophoresis with anti-human-IgG and silver stain. The lower image quality can be explained because we work with microgels that subsequently were scanned in



identical OCB in CSF and serum (Fig. 1b). *OCB pos+/pos* was defined as identical OCB in CSF and serum plus additional OCB in the CSF (Fig. 1b).

Results

OCB analyses were done at least twice in 144 patients with confirmed diagnoses (2× in 115 patients, 3× in 16 patients,

4× in four patients, 5× in two patients, 6× in four patients, 7× in one patient, and 10× in two patients). There was no change in the result of OCB in 109 cases. In 16 of them, OCB were analyzed more often than twice, and the results were also unchanged in those analyses. In 35 cases, OCB changed over time. In 13 of these cases, OCB were analyzed more than twice.

The group of patients with stable OCB included 43 women and 66 men. At the date of the first LP, the age of

Table 1 Overview of the change of OCBs

Diagnosis	N	Time between CSF analysis (days), mean (range)		Column 1 (C1) Unchanged OCB neg	Column 2 (C2) Unchanged OCB pos	Column 3 (C3) Unchanged OCB pos/pos	Column 4 (C4) OCB neg-> pos	Column 5 (C5) OCB neg-> pos+/ pos	Column 6 (C6) OCB neg-> pos/ pos	Column 7 (C7) OCB pos-> pos+/ pos	Column 8 (C8) OCB pos-> pos/ pos	Column 9 (C9) OCB pos/pos-> pos+/pos	Column 10 (C10) OCB pos+/ pos-> pos	Column 11 (C11) OCB pos-> neg	Reason for further LP, if available		
Autoimmune	62	750 (5-3256)	CIDP	3 ^{1a+1b, 2}			1 ^{1a+1b+2a}								C1: clinical deterioration; C4: follow-up, later on, multiple sclerosis is the additional suspected diagnosis (suspected diagnosis was already made when OCBs were still negative)		
			Collagenosis	1									1 ^{1a+1c}	1 ^{1a+1c}	C10 and 11: clinical deterioration/ new symptoms		
			GBS	2 ²													
			Morbus Behcet							1 ^{1a+1c}							C6: follow-up
			MS		16 1b+4a, 1c+4a; 6; 1c+4a; 1c+7; 1b+4a; 1c+4a; 1c; 1c; 1c		1 ³	1	1	3 ^{4a; 1b+4; 1b+4a}						2 ^{1a+1c; 1a}	C2: two cases in the context of a study, C5: diagnosis, C6: follow-up/ diagnosis; C7: follow-up; C11: clinical deterioration, follow-up
			CIS		3	3		2 ^{1a+1b}									C2: follow-up for exclusion of neuroborreliosis (positive serologic testing for borreliosis); C4: follow-up
			Mononeuritis multiplex		2												
			Myelitis		2 ^{1c}	2 ^{8; 1c+6}		1									C4: clinical deterioration
			Narcolepsy/ Cataplexy		2												
			NMO		1 ^{1b}			2 ^{1a+1b}									C4: clinical deterioration
			Neuro-sarcoidosis			2 ^{1a+1c; 1c}										2 ^{1b; 1a+1b}	C2: clinical deterioration
			Paraneoplasm								1 ^{1c}			1 ^{1c+2}		1 ^{1c}	C7 and C11: follow-up
Vasculitis			1 ^{1a+1b}														
Infectious	27	459 (6-2122)	HIV	2	2												
			Meningitis/ Meningo-encephalitis	3 ⁶	3 ^{1b+6; 3+6}		4 ^{1+1b+3; 6, 6}									C1 and C4: follow-up	
			Myelo-radiculitis	3 ^{1b; 1b+6}											1 ^{1c}	C1: new symptoms, follow-up, C11: follow-up (clinical improvement)	
			PML				1 ¹								1 ¹	C4: clinical deterioration	
			SSP		2												
			Neuro-borreliosis		2 ^{6; 1c+6}			1 ^{1b+6}									
			Neuroleues		1 ⁶	1 ⁶											C1 and C2: follow-up

Table 1 continued

Diagnosis	N	Time between CSF analysis (days), mean (range)		Column 1 (C1)	Column 2 (C2)	Column 3 (C3)	Column 4 (C4)	Column 5 (C5)	Column 6 (C6)	Column 7 (C7)	Column 8 (C8)	Column 9 (C9)	Column 10 (C10)	Column 11 (C11)	Reason for further LP, if available		
				Unchanged OCB neg	Unchanged OCB pos	Unchanged OCB pos/pos	OCB neg-> pos	OCB neg-> pos+/ pos	OCB neg-> pos/ pos	OCB pos-> pos+/ pos	OCB pos-> pos/ pos	OCB pos-> pos/pos	OCB pos/pos-> pos/pos	OCB pos+/ pos-> pos		OCB pos-> neg	
Neurodegenerative	16	457 (8-2740)	Dementia	3	1					1		1 ¹			C1: follow-up, clinical deterioration; C6: occurrence of an autoimmune disease at the date of the second LP; C8: follow-up, JC Virus positive at the date of 1. LP, negative at 2. LP		
			Motor neuron disease	1		1											
			MSA	1													
			Neurodegenerative disease	3 ^{1a,2}													C1: follow-up
			Spinal canal stenosis	2													
			Spino-cerebellar ataxia								1						C6: follow-up
Neurovascular	6	806 (7-2699)	Encephalopathy vascular	3	1										C1: follow-up, exclusion of NPH		
			Hemorrhage			1											
			Ischemia	1													
Neuro-oncological	6	52 (1-138)	Lymphoma CNS				1								C4: follow-up/ diagnosis, clinical deterioration		
			Meningeoma	1													
			Metastasis/ Meningeosis carcinomatosa	1	1												
			Tumour mass	1	1												
Others	27	181 (88-274)	Facial nerve paresis		2 ^{1c+6}										C2: follow-up, no clear clinical recovery C1: clinical deterioration		
			550 (12-1614)	Headache	3												
			1052 (13-2091)	Mitochondrial disease	2												
			1643	Morbus Fahr	1												
			249 (223-274)	Myelopathy	2												
			17	Neuro-psychiatric deficit	1												
			8	NPH			1										
			1581 (77-3533)	Others	3	3								1		C11: follow-up	
			2482	PNP	1												
			1191 (81-2300)	Pseudotumor cerebri	2												
			779	Restless legs Syndrome	1												
			471 (24-1541)	Seizure disorder	4											C1: another non-convulsivus status epilepticus	

CIDP chronic inflammatory demyelinating polyneuropathy, CIS clinically isolated syndrome, GBS Guillain–Barré syndrome, MS multiple sclerosis, MSA multisystem atrophy, NMO neuromyelitis optica device, NPH normal pressure hydrocephalus, PML progressive multifocal leukoencephalopathy, PNP polyneuropathy, SSP subacute sclerosing panencephalitis

¹ Under immunosuppressive therapy

^{1a} Start immunosuppressive therapy between first and second CSF analysis

^{1b} Steroid therapy

^{1c} Steroid therapy between first and second CSF analysis

² Immunomodulating therapy (IVIG) between first and second CSF analysis

^{2a} Immunomodulating therapy (IVIG) before first CSF analysis

³ Autoimmune disease and immunosuppressive therapy

⁴ Under immunomodulating therapy (disease modifying therapy)

^{4a} Start immunomodulating therapy (disease modifying therapy) between first and second CSF analysis

⁵ Under immunomodulating therapy (disease modifying therapy) and immunosuppressive therapy

⁶ Antiviral therapy/antibiotic therapy

⁷ Plasmapheresis between first and second CSF analysis

individuals ranged from 18 to 80 years (median, 44 years), and at the second one from 18 to 81 years (median, 47 years). The LP were done between April 1999 and July 2010. The time span between the LP ranged from 1 to 3,533 days (median, 241 days). *Unchanged OCB neg* appeared in 65 patients with mainly neurodegenerative and neurovascular diseases or other widespread diagnosis like headache or epilepsy and particularly without autoimmune or infectious CNS disease (Table 1, column 1). An intrathecal only OCB synthesis (*unchanged OCB pos*) was repeatedly found in 41 individuals with mostly autoimmune or infectious CNS diseases including MS/clinically isolated syndrome (CIS), myelitis, neurosarcoidosis, vasculitis, HIV, meningitis/meningoencephalitis, and neurolyues (Table 1, column 2). A systemic OCB synthesis was repeatedly observed in three patients; each one with hemorrhage, motor neuron disease, and normal pressure hydrocephalus (*unchanged OCB pos/pos*).

The group of patients with newly appearing or with disappearing OCB included 21 women and 14 men (Table 1, orange and blue columns). At the date of the first LP the age ranged from 16 to 72 years (median, 51 years) and at the second one from 21 to 75 years (median, 52 years). The LP were performed between July 1999 and July 2010. The time span between the LP ranged from 6 to 2,942 days (median, 339 days); in the subgroup with newly emerging OCB from 6 to 2,942 days (median, 329 days), and in the group with disappearing OCB from 53 to 1,049 (median, 347 days).

The shift *OCB neg* → *OCB pos* appeared in autoimmune, infectious, and neurooncological diseases including MS/CIS, NMO, chronic inflammatory demyelinating polyneuropathy (CIDP), myelitis, progressive multifocal leukoencephalopathy (PML), neuroborreliosis, meningitis/meningoencephalitis, primary CNS lymphoma. Noteworthy, in the patient with CIDP, the additional diagnosis of possible MS was made between the two LP. The shift *OCB neg* → *OCB pos+/pos* appeared in one MS patient. The change *OCB neg* → *OCB pos/pos* occurred in autoimmune and neurodegenerative diseases (Table 1, column 6). In the patient with dementia, the diagnosis of an autoimmune

disease (Basedow's disease) was made in addition at the time of the second LP. The shift *OCB pos* → *OCB pos+/pos* appeared in autoimmune diseases including MS and smoldering lymphoma with paraneoplastic polyradiculoneuropathy. The shift *OCB pos* → *OCB pos/pos* was only seen in one patient with dementia. Finally, the shift *OCB pos/pos* → *OCB pos+/pos* was only seen in multiple myeloma with emerging paraneoplastic polyneuropathy.

In the group of patients with a loss of OCB, the shift *OCB pos+/pos* → *OCB pos* was seen in one patient with autoimmune disease (collagenosis, M. Sjögren with CNS involvement). An immunosuppressive therapy with azathioprine had been established before the second LP. The shift *OCB pos* → *OCB neg* occurred in autoimmune and infectious diseases including collagenosis with CNS involvement, MS, neurosarcoidosis, breast cancer with paraneoplastic sensory polyneuropathy and leukoencephalopathy of unknown specification, myeloradiculitis, and PML.

In the patient with myeloradiculitis steroid therapy and in the patient with collagenosis cyclophosphamide, hydroxychloroquine and steroids had been started between LP. Moreover, in the MS patients, immunosuppressive therapy had been started between LP because of the additional diagnosis of CIDP and oligoarthritis with positive lupus serologic testing, respectively. Both patients with neurosarcoidosis had been treated with steroids between the LP, one with methotrexate in addition. The patient with PML suffered from chronic lymphocytic leukemia and had been treated with several chemotherapies and allogenic bone marrow transplantation between the two LP.

In all of the 24 MS patients included in our analysis, OCB were found positive at least once (Table 1, column 2, 4–7 and 11). Of the 24 MS patients, 19 had the diagnosis relapsing remitting MS (RRMS). In three of these RRMS patients, OCB were initially negative in the early phase of disease, but were detected in a subsequent analysis (Table 2, column 3–5). Eight patients had the diagnosis of CIS. Each three of them showed and did not show OCB in both LP (time span, 11–482 and 46–333 days, respectively), two had newly emerging OCB in the second LP (time span, 329–1,407 days).

Table 2 Overview of the change of OCBs in MS patients

Diagnosis	N	Time between CSF analysis (days), mean (range)	Column 1 <i>Unchanged OCB neg</i>	Column 2 <i>Unchanged OCB pos</i>	Column 3 <i>OCB neg</i> → <i>pos</i>	Column 4 <i>OCB neg</i> → <i>pos+/pos</i>	Column 5 <i>OCB neg</i> → <i>pos/pos</i>	Column 6 <i>OCB pos</i> → <i>pos+/pos</i>	Column 7 <i>OCB pos</i> → <i>neg</i>
RRMS	19	953 (64–3,256)		14	1	1	1	2	
PPMS	1	331		1					
SPMS	4	852 (26–2,942)		1				1	2
CIS	8	345 (11–1,407)	3	3	2				

RRMS relapsing-remitting multiple sclerosis, PPMS primary progressive multiple sclerosis, SPMS secondary progressive multiple sclerosis, CIS clinically isolated syndrome

Discussion

Differential diagnoses of diseases associated with CSF IgG OCB include infections, systemic and CNS inflammatory disorders, peripheral neuropathies, and others [10, 13, 16, 19–21].

In clinical practice, OCB are often investigated in the diagnostic work-up of inflammatory CNS disorders, in particular MS. In our study, OCB were not only observed in MS patients but also in patients with several other autoimmune and with infectious CNS diseases, as expected. However, it is noteworthy that OCB were found positive at least once in all of 24 MS patients. Time spans between an initially negative and the second, positive result ranged from 6.6 to 60 months (mean, 25 months). Thus, although presence of OCB in the CSF are no longer criteria for the diagnosis of RRMS and are only a facultative criteria for the diagnosis of primary progressive MS [11], our data suggest that it might be reasonable to do a second LP if OCB are negative at first in cases of suspected MS. If patients continue to have no intrathecal OCB production, it may become necessary to reconfirm an MS diagnosis.

In one-quarter of patients with repeated OCB analyses, the OCB result changed over time. A change to a positive result was often observed in infectious diseases. For example, in four patients with meningitis or meningoencephalitis, OCB were initially negative, but positive in the second LP 6–1,471 days (mean, 17 days) later, presumably corresponding to a post-infectious immunological CNS response.

Changes from a positive towards a negative OCB results were less frequent, observed in autoimmune disorders including MS, neurosarcoidosis, and collagenosis as well as in PML. Interestingly, an immunosuppressive therapy had been established before the second LP in the patients with MS and collagenosis and in one of the patients with neurosarcoidosis (Table 1). These immunosuppressive therapies may be assumed as the reason for the disappearance of OCB, which is unusual in MS patients [16, 22]. In addition to immunosuppression, the treatment with natalizumab can also lead to the disappearance of OCB from the CSF of MS patients [17, 23]. In accordance, Harrer and colleagues [23] showed that CSF IgG production is reduced by natalizumab therapy in MS. Fingolimod treatment also influences the number of lymphocytes in the CNS in neuroinflammatory diseases. Kowarik and colleagues [24] observed that treatment with fingolimod reduces the CSF leukocyte count in MS patients, but the B cell levels were more or less unchanged. Consequently, CSF IgG levels and occurrence of OCB were not influenced. Our data suggest that immunosuppression reduces B cell activity in the CNS in MS patients. It is tempting to speculate that a loss of OCB may be associated with response to immunosuppressive

therapy of autoimmune diseases affecting the CNS. This is in line with other studies showing that the degree of humoral CNS immune response may be linked to the prognosis, i.e., the absence (or disappearance) of OCBs in MS patients may be associated with a better prognosis [22].

In five of 19 RRMS patients of our study population, OCB were initially negative or restricted to the CSF, but became positive or also detectable in the serum in the second investigation (Table 2, column 3–6). In one of these five patients, MS was diagnosed at the time of the second LP, and in another patient, the MS diagnosis was made later on. Further, one RRMS patient had initially positive OCB, became negative during natalizumab treatment, but positive again at PML onset (already published by Harrer 2013 [23]). This is in line with the observation of a switch from negative to positive OCB in another patient at PML onset (Table 1, column 4) as well as stable positive OCB in a patient with known PML suffering from HIV (Table 1, column 2). In the same context, Mazzeo et al. [25] found positive OCB in patients with PML.

In conclusion, the analysis of CSF OCB still plays an important role in the diagnostic process of autoimmune diseases affecting the CNS, particularly MS. OCB results may change over time, which can be explained by clinical conditions. Such variability must be taken into account for the interpretation of OCB results.

Limitations of our study are the retrospective analysis of data and the small number of cases per diagnosis. Furthermore, the second or further lumbar punctures were usually done for new clinical situations or for verification of uncertain diagnoses, which leads to selection bias favoring a higher amount of patients with changes in the OCB status.

Conflicts of interest The authors declare that they have no conflicts of interest.

References

1. Brown PD, Davies SL, Speake T, Millar ID (2004) Molecular mechanisms of cerebrospinal fluid production. *Neuroscience* 129:957–970
2. Battal B, Kocaoglu M, Bulakbasi N, Husmen G, Tuba Sanal H, Tayfun C (2011) Cerebrospinal fluid flow imaging by using phase-contrast MR technique. *Br J Radiol* 84:758–765
3. Reese TS, Karnovsky MJ (1967) Fine structural localization of a blood–brain barrier to exogenous peroxidase. *J Cell Biol* 33:207–217
4. Reiber H, Peter JB (2001) Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. *J Neurol Sci* 184:101–122
5. Ransohoff RM, Kivisäkk P, Kidd G (2003) Three or more routes for leukocyte migration into the central nervous system. *Nat Rev Immunol* 3:569–581

6. Greter M, Heppner FL, Lemos MP et al (2005) Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. *Nat Med* 11:328–334
7. Owens T, Bechmann I, Engelhardt B (2008) Perivascular spaces and the two steps to neuroinflammation. *J Neuropathol Exp Neurol* 67:1113–1121
8. Zipoli V, Hakiki B, Portaccio E et al (2009) The contribution of cerebrospinal fluid oligoclonal bands to the early diagnosis of multiple sclerosis. *Mult Scler* 15:472–478
9. Tintoré M, Rovira A, Río J et al (2008) Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? *Neurology* 70:1079–1083
10. De Bourahoui A, Seze J, Gutierrez R et al (2004) CSF isoelectrofocusing in a large cohort of MS and other neurological diseases. *Eur J Neurol* 11:525–529
11. Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. *Ann Neurol* 69:292–302
12. Freedman MS, Thompson EJ, Deisenhammer F et al (2005) Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. *Arch Neurol* 62:865–870
13. Christenson RH, Behlmer P, Howard JF, Winfield JB, Silverman LM (1983) Interpretation of cerebrospinal fluid protein assays in various neurologic diseases. *Clin Chem* 29:1028–1030
14. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic's syndrome). *Neurology* 53:1107–1114
15. Jacob A, McKeon A, Nakashima I, Sato DK, Elson L, Fujihara K, de Seze J (2013) Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. *J Neurol Neurosurg Psychiatry* 84:922–930
16. McLean BN, Miller D, Thompson EJ (1995) Oligoclonal banding of IgG in CSF, blood–brain barrier function, and MRI findings in patients with sarcoidosis, systemic lupus erythematosus, and Behçet's disease involving the nervous system. *J Neurol Neurosurg Psychiatr* 58:548–554
17. Von Glehn F, Farias AS, de Oliveira ACP et al (2012) Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patients. *Mult Scler* 18:1038–1041
18. Lechner-Scott J, Spencer B, de Malmanche T et al (2012) The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. *Mult Scler* 18:974–982
19. Alexander EL, Malinow K, Lejewski JE, Jerdan MS, Provost TT, Alexander GE (1986) Primary Sjögren's syndrome with central nervous system disease mimicking multiple sclerosis. *Ann Intern Med* 104:323–330
20. Scott TF, Seay AR, Goust JM (1989) Pattern and concentration of IgG in cerebrospinal fluid in neurosarcoidosis. *Neurology* 39:1637–1639
21. Ernerudh J, Olsson T, Lindström F, Skogh T (1985) Cerebrospinal fluid immunoglobulin abnormalities in systemic lupus erythematosus. *J Neurol Neurosurg Psychiatr* 48:807–813
22. Correale J, de los Milagros Bassani Molinas M (2002) Oligoclonal bands and antibody responses in multiple sclerosis. *J Neurol* 249:375–389
23. Harrer A, Tumani H, Niendorf S et al (2013) Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy. *Mult Scler* 19:1209–1212
24. Kowarik MC, Pellkofer HL, Cepok S et al (2011) Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. *Neurology* 76:1214–1221
25. Mazzarello P, Poloni M, Ceroni M, Scelsi R (1985) Is progressive multifocal leukoencephalopathy associated with intrathecal IgG synthesis? *J Neuroimmunol* 10:167–172